Compare TMCI & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMCI | VCRE |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 316.4M |
| IPO Year | 2021 | 2026 |
| Metric | TMCI | VCRE |
|---|---|---|
| Price | $4.46 | $9.19 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.77 | N/A |
| AVG Volume (30 Days) | ★ 202.8K | 17.0K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.17 | $9.50 |
| 52 Week High | $7.08 | $13.15 |
| Indicator | TMCI | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 30.06 |
| Support Level | $4.31 | N/A |
| Resistance Level | $4.47 | $13.00 |
| Average True Range (ATR) | 0.20 | 0.63 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 31.33 | 22.92 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.